MAPT and Alzheimer disease: The main objectives of the present study were the following: (1) to determine whether FACEmemory® was a sensitive tool for the detection of cognitive impairment, (2) to assess whether performances on FACEmemory® were correlated with those on the S-FNAME (paper-and-pencil version with 16 images), and (3) to determine whether performances on FACEmemory® were related to AD biomarkers in CSF (amyloid beta 42 [Aβ42], p-tau, and Aβ42/p-tau ratio).